Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 2/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22498638 | 0.85 | ALDH1A1 (0.40) | AAK1ATRMETAP1 | |
| SCHEMBL30755793 | 0.83 | NPC1 (0.40) | AAK1METAP1 | |
| SCHEMBL22498359 | 0.82 | AAK1 (0.37) | AAK1ATRMETAP1LCKBRD9 | |
| SCHEMBL30756612 | 0.81 | AAK1 (0.37) | AAK1METAP1GSK3BDYRK1A | |
| SCHEMBL15511586 | 0.81 | AAK1 (0.39) | AAK1ATRMETAP1LCKBRD9 | |
| SCHEMBL30755612 | 0.80 | KDM4E (0.40) | AAK1ATRMETAP1LCKBRD4 | |
| SCHEMBL30756371 | 0.80 | AAK1 (0.42) | AAK1RXFP1 | |
| SCHEMBL30755602 | 0.80 | AAK1 (0.38) | AAK1ATRMETAP1LCKBRD9 | |
| SCHEMBL31441184 | 0.80 | AAK1 (0.43) | AAK1ATRMETAP1LCKBRD9 | |
| SCHEMBL32667169 | 0.79 | AAK1 (0.40) | AAK1GSK3BP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218679-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218679-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, CYSLTR1 | AAK1 4091/4885ATR 3946/4885METAP1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.